Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2017 / Feb / This Month in Business
Professional Development

This Month in Business

Extensive staff cuts at Ophthotech, a startup applying AI to healthcare, and Trefoil and the NIH team up…

By Roisin McGuigan 2/6/2017 1 min read

Share

• The ranibizumab 0.5 mg prefilled syringe (PFS), approved by the FDA late last year, is now available to US ophthalmologists to treat wet AMD, macular edema after retinal vein occlusion and myopic choroidal neovascularization. •Roche acquired ForSight Vision4, a biotechnology company that is developing refillable intravitreal implant for use with VEGF-A-targeting drugs.

• Following disappointing phase III trial results with Fovista, Ophthotech announced in a recent SEC filing that it is planning to cuts staff numbers by around 80 percent. • Trefoil Therapeutics has announced its plans to collaborate with the NIH to accelerate the development of their engineered FDF-1 compound, TTHX1114, for the treatment of Fuchs endothelial corneal dystrophy. • Hemera Biosciences report that the FDA has granted “safe to proceed” status to their investigational new drug application for HMR59, a gene therapy that’s intended to treat (or at least slow the progression of) dry AMD. • Optics and imaging giant Nikon has partnered with Verily, the life sciences branch of Google’s parent company Alphabet Inc., to develop machine learning-enabled retinal imaging. The technology will be focused on enhancing screening of diabetic retinopathy and diabetic macular edema to improve referrals to eye care specialists. • Former Googler Adrian Aoun has launched a healthcare startup, Forward, that aims to use artificial intelligence to improve healthcare. Aoun says the company will be built on “beautiful software and hardware, the likes of which we’ve come to know and love from companies like Tesla.”

About the Author(s)

Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as a deputy editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

More Articles by Roisin McGuigan

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: